Antidepressants Prescribed For IBS Tied To Higher Death Risk

Millions of Americans take antidepressants to calm their irritable bowels. Now, a large new study suggests those pills may come with potential risks that researchers are only now flagging. Drawing on a database covering nearly 143 million patients, researchers found that antidepressants, the single most commonly prescribed medication class for irritable bowel syndrome, were associated with a 35 percent higher risk of death compared to IBS patients who never took them. One popular over-the-counter anti-diarrheal and one prescription anti-diarrheal fared even worse.

IBS affects roughly 10 to 15 percent of people worldwide, a chronic gut disorder marked by abdominal pain and unpredictable bathroom habits. Treatment revolves around managing symptoms, often for years or decades, with no cure available. Despite several drugs carrying formal FDA approval, fewer than one in five patients with the constipation type and fewer than one in ten with the diarrhea type have ever been prescribed those approved options. Doctors frequently turn to antidepressants instead, which medical guidelines recommend as a second-line treatment.

That gap between what’s approved and what’s actually prescribed motivated a team at Cedars-Sinai in Los Angeles. Their findings, published in Communications Medicine, don’t prove antidepressants directly cause early death in IBS patients. But the size and consistency of the signal, holding steady across age groups, sexes, body weights, and racial and ethnic categories, has the authors calling for “cautious prescribing and further research.”

Inside a Massive IBS Medications Study

Researchers used TriNetX, a large U.S. electronic health records database pulling anonymous medical data from 106 healthcare organizations across all 50 states. Adult IBS patients between 18 and 65, diagnosed between January 2005 and January 2023, were included. After applying eligibility criteria, the main analysis covered 669,083 patients.

To make fair comparisons, researchers identified a closely matched patient for every patient who took a given medication, pairing each on 56 health factors like age, existing conditions, and medication history. The primary outcome tracked was death from any cause, over follow-up periods ranging from six months to 15 years. Antidepressants were the most commonly prescribed medication in the group, used by 52.3 percent of patients, followed by antispasmodics at 22.1 percent.

Antidepressants and IBS: What the Numbers Showed

Among antidepressant users, 1.6 percent died during follow-up versus 1.01 percent of matched non-users, a relative increase of roughly 35 percent. In absolute terms the raw gap in death rates was smaller, but it held consistent across every demographic group researchers examined. SSRIs, the class that includes Prozac, Zoloft, and Lexapro, carried a 32 percent increased risk. Older tricyclic antidepressants came in at 27 percent, and SNRIs showed a comparable 32 percent increase. Mirtazapine stood out sharply: 5.29 percent of users died during follow-up versus 2.27 percent of non-users, roughly a doubling of risk.

Higher refill counts were associated with higher mortality risk, with patients reaching 20 refills showing nearly double the risk of non-users.

Antispasmodics showed no increase in death risk. When researchers directly compared antidepressant users to antispasmodic users in an analysis designed to approximate a clinical trial using observational data, survival curves began pulling apart after about five years, with antidepressant users faring progressively worse.

Safety Signals for IBS-D and IBS-C Medications

For patients with diarrhea-predominant IBS, two medications were associated with notably higher risks. Loperamide, the active ingredient in over-the-counter Imodium, was associated with a 2.39-fold increase in mortality risk. Diphenoxylate, a prescription anti-diarrheal, carried a 1.89-fold increase. Both drugs activate the same type of receptor targeted by opioid painkillers. At normal doses, loperamide is not supposed to reach the brain the way opioids do, but excessive use has been linked to dangerous heart rhythm problems. Low case numbers prevented researchers from identifying exact causes of death in these groups.

Other diarrhea-focused medications cleared the bar. Bile acid-binding drugs, the antibiotic rifaximin, the FDA-approved drug eluxadoline, and antispasmodics all showed no statistically significant increase in mortality.

For constipation-predominant IBS, results were largely reassuring. A common laxative ingredient found in products like MiraLAX, along with newer prescription drugs that help the intestines produce more fluid, showed no association with higher death rates. Antidepressants, though, stood out again: those patients carried a 56 percent higher risk of death compared to non-users.

Beyond mortality itself, IBS patients on antidepressants experienced significantly higher rates of high blood pressure, heart rhythm disturbances, heart failure, stroke, dangerous falls, gastrointestinal bleeding, and obesity. Suicidal ideation was about five times more likely to be recorded in medical data among antidepressant users than non-users.

Every FDA-approved IBS medication tested, including lubiprostone, linaclotide, plecanatide, tenapanor, eluxadoline, and rifaximin, showed no association with increased mortality. About one in five gastroenterologists and primary care doctors in the United States recommend antidepressants for IBS most or all of the time, according to prior survey data cited in the paper.

Antidepressants remain the go-to for more than half of IBS patients in this dataset, a wide gap between prescribing habits and the safety signals now emerging from the data. None of this means patients should stop their medication without talking to a doctor. But it does suggest that long-term conversations about IBS treatment deserve a harder look at what those pills may be doing beyond settling an angry gut.

---

Disclaimer: This article reports on an observational study and does not establish cause and effect. Readers should consult a qualified healthcare provider before making any changes to their medication regimen.

---